Goodwin, OncoMax in MAb Pact

Goodwin Biotechnology, Inc. (GBI) and OncoMax, LLC have signed agreement for cell line engineering and manufacturing of a monoclonal antibody expressed in a mammalian cell line. The monoclonal antibody will be engineered with GBI’s collaborative partner Rafagen, and GBI will then evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for use and evaluation in clinical trials as a potential treatment for renal cell carcinoma.

“This is an exciting project for us,” noted Muctarr Sesay, Ph.D., vice president of Process Development at GBI. “It truly represents ‘one-stop-shopping’ for our clients because we can take a client’s cDNA, engineer the cell line with the help of Rafagen, one of our collaborative partners, which will provide us with three stable, high-producing clones.”

“Our drug candidate OM-RCA-001 is a humanized monoclonal antibody and establishing a high producing cell line and creating a cell bank is one of the key stages of the product’s development. We are pleased to partner with GBI in this, since GBI is known for its high quality services in this line of work,” said Nikolay Golub, Ph.D., project manager at Maxwell Biotech Group, where OncoMax is a portfolio company. “OM-RCA-001 blocks a specific target of kidney tumor cells, affecting the mechanisms of tumor progression and resistance. If all the clinical trials are successful we will have a novel biopharmaceutical that can be prescribed both as first-line treatment and as treatment in the second and subsequent lines after failure of other types of targeted therapy.”